Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: The ROSORC trial

G. Procopio, E. Verzoni, S. Bracarda, S. Ricci, C. Sacco, L. Ridolfi, C. Porta, R. Miceli, N. Zilembo, E. Bajetta

Research output: Contribution to journalArticle

Abstract

Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability. Results: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (P=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand-foot syndrome, hypertension, and diarrhoea. Grade 3-4 adverse events were reported for 38 and 25% of patients receiving combination and single-agent treatment, respectively. Conclusion: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.

Original languageEnglish
Pages (from-to)1256-1261
Number of pages6
JournalBritish Journal of Cancer
Volume104
Issue number8
DOIs
Publication statusPublished - Apr 12 2011

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Disease-Free Survival
Hand-Foot Syndrome
Asthenia
sorafenib
Diarrhea
Hypertension
Therapeutics

Keywords

  • immunotherapy
  • interleukin-2
  • renal cell carcinoma
  • sorafenib
  • targeted therapies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma : The ROSORC trial. / Procopio, G.; Verzoni, E.; Bracarda, S.; Ricci, S.; Sacco, C.; Ridolfi, L.; Porta, C.; Miceli, R.; Zilembo, N.; Bajetta, E.

In: British Journal of Cancer, Vol. 104, No. 8, 12.04.2011, p. 1256-1261.

Research output: Contribution to journalArticle

@article{4412973ad1274807ab5a7e1f553b99f6,
title = "Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: The ROSORC trial",
abstract = "Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability. Results: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (P=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand-foot syndrome, hypertension, and diarrhoea. Grade 3-4 adverse events were reported for 38 and 25{\%} of patients receiving combination and single-agent treatment, respectively. Conclusion: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.",
keywords = "immunotherapy, interleukin-2, renal cell carcinoma, sorafenib, targeted therapies",
author = "G. Procopio and E. Verzoni and S. Bracarda and S. Ricci and C. Sacco and L. Ridolfi and C. Porta and R. Miceli and N. Zilembo and E. Bajetta",
year = "2011",
month = "4",
day = "12",
doi = "10.1038/bjc.2011.103",
language = "English",
volume = "104",
pages = "1256--1261",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma

T2 - The ROSORC trial

AU - Procopio, G.

AU - Verzoni, E.

AU - Bracarda, S.

AU - Ricci, S.

AU - Sacco, C.

AU - Ridolfi, L.

AU - Porta, C.

AU - Miceli, R.

AU - Zilembo, N.

AU - Bajetta, E.

PY - 2011/4/12

Y1 - 2011/4/12

N2 - Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability. Results: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (P=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand-foot syndrome, hypertension, and diarrhoea. Grade 3-4 adverse events were reported for 38 and 25% of patients receiving combination and single-agent treatment, respectively. Conclusion: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.

AB - Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability. Results: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (P=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand-foot syndrome, hypertension, and diarrhoea. Grade 3-4 adverse events were reported for 38 and 25% of patients receiving combination and single-agent treatment, respectively. Conclusion: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.

KW - immunotherapy

KW - interleukin-2

KW - renal cell carcinoma

KW - sorafenib

KW - targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=79954438593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954438593&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.103

DO - 10.1038/bjc.2011.103

M3 - Article

C2 - 21448165

AN - SCOPUS:79954438593

VL - 104

SP - 1256

EP - 1261

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -